Compare Newmont Corporation (NEM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs 10X Genomics Inc — how do they compare? Newmont Corporation trades at $117.8 (market cap $121.75B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: Newmont Corporation is far larger — about 12.1× 10X Genomics Inc's market cap, and Newmont Corporation pays a 0.9% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and 10X Genomics Inc for 91 Days on average.
| NEM | TXG | |
|---|---|---|
Market Cap | $121.75B | $10.07B |
Volume | 5,421,125 | 5,657,286 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $97.74 |
52-Week Low | $78.63 | $11.48 |
Typical Hold Time | 58 Days | 91 Days |
Enterprise Value | $118.34B | $9.59B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont (NEM) trades at $118.23, up 4.13% today, supported by strong earnings beats and record free cash flow. The stock shows a bearish technical signal near key support at $114, while fundamentals are robust with a P/E of 14.57, net income margin of 33.36%, and revenue growth to $22.67B in 2025. Analyst consensus is strongly bullish with a $136.83 price target.
The outlook for NEM is positive, driven by operational improvements and a constructive gold market. Key risks include gold price volatility and execution of growth projects. With no analyst sell ratings and strong institutional interest, the stock presents a compelling opportunity for investors seeking exposure to a leading gold producer.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
